Research programme: immunoproteasome inhibitors - Onyx Pharmaceuticals

Drug Profile

Research programme: immunoproteasome inhibitors - Onyx Pharmaceuticals

Alternative Names: ONX 0914; ONYX 0914; PR-957

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Proteolix
  • Developer Onyx Pharmaceuticals; Proteolix
  • Class Epoxy compounds; Ketones; Peptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Autoimmune disorders; Haematological malignancies

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
  • 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen
  • 14 Mar 2012 Preclinical development is ongoing for Autoimmune disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top